Moderna (MRNA) Schedules Multiple Product Launches for 2027-2028, Implements Organizational Restructuring

Moderna Inc. (MRNA) announced on June 16, 2026, plans to launch multiple products in 2027 and 2028, paired with organizational changes to support the expanded pipeline. The biotech company has not disclosed specific product candidates or launch timelines within the two-year window. The organizational restructuring signals Moderna's shift from a single-product company to a multi-product commercial operation. The changes come as the company seeks to diversify beyond its COVID-19 vaccine franchise, which has faced declining revenue as pandemic demand wanes. The company's pipeline includes mRNA-based candidates in respiratory diseases, oncology, and rare diseases.